Tenax Therapeutics Stock Performance
| TENX Stock | USD 6.37 0.04 0.62% |
On a scale of 0 to 100, Tenax Therapeutics holds a performance score of 17. The entity has a beta of -0.48, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Tenax Therapeutics are expected to decrease at a much lower rate. During the bear market, Tenax Therapeutics is likely to outperform the market. Please check Tenax Therapeutics' potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether Tenax Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
17 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Tenax Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Tenax Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.63 | Five Day Return (2.46) | Year To Date Return (2.75) | Ten Year Return (99.99) | All Time Return (100.00) |
Last Split Factor 1:80 | Dividend Date 2018-02-26 | Last Split Date 2024-01-03 |
1 | Tenax Therapeutics Upgraded to Strong-Buy by Leerink Partnrs | 10/25/2024 |
2 | Tenax Therapeutics Q3 Earnings Snapshot - Barchart | 11/12/2024 |
3 | Stonepine Capital Management, LLC Increases Stake in Tenax Therapeutics Inc | 11/14/2024 |
4 | Acquisition by Rich Stuart of 100000 shares of Tenax Therapeutics at 0.62 subject to Rule 16b-3 | 11/22/2024 |
5 | Insider Trading | 12/02/2024 |
6 | Acquisition by Almenoff June Sherie of 100000 shares of Tenax Therapeutics at 5.94 subject to Rule 16b-3 | 12/10/2024 |
7 | Acquisition by Christopher Giordano of 1250000 shares of Tenax Therapeutics at 5.94 subject to Rule 16b-3 | 12/27/2024 |
8 | Acquisition by Armistice Capital, Llc of tradable shares of Tenax Therapeutics subject to Rule 16b-3 | 01/02/2025 |
| Begin Period Cash Flow | 2.1 M |
Tenax |
Tenax Therapeutics Relative Risk vs. Return Landscape
If you would invest 405.00 in Tenax Therapeutics on October 20, 2024 and sell it today you would earn a total of 232.00 from holding Tenax Therapeutics or generate 57.28% return on investment over 90 days. Tenax Therapeutics is currently generating 0.8131% in daily expected returns and assumes 3.7378% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Tenax, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tenax Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tenax Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tenax Therapeutics, and traders can use it to determine the average amount a Tenax Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2175
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TENX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.74 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.81 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Tenax Therapeutics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tenax Therapeutics by adding it to a well-diversified portfolio.
Tenax Therapeutics Fundamentals Growth
Tenax Stock prices reflect investors' perceptions of the future prospects and financial health of Tenax Therapeutics, and Tenax Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tenax Stock performance.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 7.73 M | ||||
| Shares Outstanding | 3.41 M | ||||
| Price To Earning | (0.35) X | ||||
| Price To Book | 0.23 X | ||||
| EBITDA | (8.23 M) | ||||
| Net Income | (7.71 M) | ||||
| Cash And Equivalents | 7.23 M | ||||
| Cash Per Share | 0.29 X | ||||
| Total Debt | 500.9 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 5.60 X | ||||
| Book Value Per Share | 27.15 X | ||||
| Cash Flow From Operations | (5.9 M) | ||||
| Earnings Per Share | (13.05) X | ||||
| Market Capitalization | 21.83 M | ||||
| Total Asset | 11.68 M | ||||
| Retained Earnings | (297.25 M) | ||||
| Working Capital | 8.1 M | ||||
| Current Asset | 21.86 M | ||||
| Current Liabilities | 3.56 M | ||||
About Tenax Therapeutics Performance
Evaluating Tenax Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Tenax Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tenax Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.3 K | 1 K | |
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (1.17) | (1.11) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (1.09) | (1.04) |
Things to note about Tenax Therapeutics performance evaluation
Checking the ongoing alerts about Tenax Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tenax Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tenax Therapeutics appears to be risky and price may revert if volatility continues | |
| Tenax Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.71 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tenax Therapeutics currently holds about 7.23 M in cash with (5.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29. | |
| Tenax Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing Tenax Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tenax Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tenax Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tenax Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tenax Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tenax Therapeutics' stock. These opinions can provide insight into Tenax Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.